Intermune Will Divest Rights to Vidara for $55M in Cash, Plus 2 Year Royalty Stream

InterMune, Inc. ITMN today announced that it has reached a definitive agreement with Vidara Therapeutics International Limited (Vidara) to sell its rights to Actimmune® (interferon gamma-1b) in a cash transaction valued at $55 million plus a two-year royalty stream.  Vidara is part of an international specialty pharmaceutical group of companies with operations in Ireland and the United States.